Tau reduction without a primary endpoint hit is either a trial failure or the most important proof-of-concept in Alzheimer’s drug development this decade — and Biogen’s Phase 2 CELIA study of diranersen forces that exact question. The topline readout showed measurable decreases in tau biomarkers alongside signals of slowed cognitive decline, yet the study did not meet its primary endpoint, a combination that will define how the field interprets this data when full results surface at AAIC in July.
The distinction between biomarker movement and clinical endpoint achievement matters enormously here. Amyloid-targeting therapies spent years in a similar purgatory — clearing plaques on PET scans while regulators and clinicians argued about whether that translated to meaningful patient benefit. Diranersen appears to be entering that same contested territory for tau. It is the first antisense oligonucleotide or tau-directed therapy of its class to reach this stage with any signal of downstream clinical effect, which is a genuinely different result from prior tau failures that produced neither biological nor functional movement. Those earlier programs collapsed at both levels simultaneously.
The broader pipeline context sharpens the stakes. With 75% of current Alzheimer’s trials now targeting pathways beyond amyloid and tau — inflammation, metabolic dysfunction, oxidative stress — the field is structurally positioning itself for combination regimens. Two anti-amyloid therapies are already approved. If tau can be validated as a second addressable node, the combination therapy framework stops being theoretical. Diranersen’s partial signal, however ambiguous, is the first data point that makes that architecture clinically plausible rather than aspirational. The CELIA design — enrolling early Alzheimer’s patients, presumably with confirmed amyloid and tau pathology at baseline — also positions any follow-on trial to test diranersen as an add-on to existing standard of care, which changes the ethical and regulatory calculus for trial design entirely.
The single marker worth tracking is the tau biomarker magnitude reported at AAIC: specifically whether CSF or plasma phospho-tau reductions reached a threshold consistent with what imaging and fluid biomarker studies have suggested correlates with synaptic preservation. If that number clears the bar established by the amyloid literature, Biogen has a legitimate path to a Phase 3 design even on a failed primary endpoint — and tau combination therapy moves from pipeline ambition to active protocol.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
